Alaproclate
Alaproclate
Alaproclate (pronounced: al-a-pro-clate) is a compound that was initially developed as an antidepressant by the pharmaceutical company AstraZeneca. However, during clinical trials, it was found to have serious side effects and its development was discontinued.
Etymology
The term "Alaproclate" is derived from the chemical name of the compound: Alanine proline claterate.
Pharmacology
Alaproclate acts as a serotonin reuptake inhibitor and glycine antagonist. It was initially developed for the treatment of depression and anxiety disorders. However, during phase II clinical trials, it was found to cause a high incidence of agranulocytosis, a serious blood disorder, leading to the discontinuation of its development.
Related Terms
- Agranulocytosis: A condition characterized by a decrease in the number of white blood cells, leading to increased susceptibility to infections.
- Serotonin: A neurotransmitter that contributes to feelings of well-being and happiness.
- Glycine: An inhibitory neurotransmitter in the central nervous system, especially in the spinal cord.
- Antidepressant: A medication used to treat major depressive disorder, anxiety disorders, or some chronic pain conditions.
See Also
External links
- Medical encyclopedia article on Alaproclate
- Wikipedia's article - Alaproclate
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski